A new image recognition algorithm uses the way humans see things for inspiration....
The context: When humans look at a new image of something, we identify what it is based on a collection of recognizable features. We might identify the species of a bird, for example, by the contour of its beak, the colors of its plume, and the shape of its feet. A neural network, however, simply looks for pixel patterns across the entire image without discriminating between the actual bird and its background. This makes the neural network more vulnerable to mistakes and makes it harder for humans to diagnose them.
How it works: Rather than train the neural network on full images of birds, researchers from Duke University and MIT Lincoln Laboratory trained it to recognize the different features instead: the beak and head shape of every species and the coloration of their feathers. Presented with a new image of a bird, the algorithm then searches for those recognizable features and makes predictions about which species they belong to. It uses the cumulative evidence to make a final decision.
An example: For a picture of a red-bellied woodpecker, the algorithm might find two recognizable features that it’s been trained on: the black-and-white pattern of its feathers and the red coloring of its head. The first feature could match with two possible bird species: the red-bellied or the red-cockaded woodpecker. But the second feature would match best with the former.
From the two pieces of evidence, the algorithm then reasons that the picture is more likely of the former. It then displays the pictures of the features it found to explain to a human how it came to its decision.
Why it matters: In order for image recognition algorithms to be more useful in high-stakes environments such as hospitals, where they might help a doctor classify a tumor, they need to be able to explain how they arrived at their conclusion in a human-understandable way. Not only is it important for humans to trust them, but it also helps humans more easily identify when the logic is wrong.
Through testing, the researchers also demonstrated that incorporating this interpretability into their algorithm didn’t hurt its accuracy. On both the bird species identification task and a car model identification task, they found that their method neared—and in some cases exceeded—state-of-the-art results achieved by non-interpretable algorithms.
To have more stories like this delivered directly to your inbox, sign up for our Webby-nominated AI newsletter The Algorithm. It's free.
Veritas Genetics, which offered to sequence people's genomes for rock-bottom prices, will cease US operations after it failed to raise a new round of financing....
Low price: The company, based in Boston, had tried to entice consumers to get their genome sequenced by lowering the price to $599 last July.
At that cost, Veritas was losing money on every genome. But it hoped to introduce a Netflix-like subscription model; customers would pay ongoing fees to learn new things from their DNA, such as disease risk predictions.
The company had sequenced between 5,000 and 10,000 genomes so far, but there were signs that demand for the service was weak.
China worry: A person familiar with the company said it was going out of business in the US because it could not find new investors given concerns it had previously taken money from China.
Veritas's main investors are all Chinese. They are Lilly Asia Venture, Simcere Pharmaceutical, and TrustBridge Partners.
The US has warned companies working in sensitive areas, including DNA data, over taking Chinese funds. In June, US regulators forced the sale of another American health company, PatientsLikeMe, because its primary investor was in China.
Veritas had been trying to raise $50 to $75 million since earlier this year, this person said, but new investors balked at the Chinese ownership.
Bad news: Veritas tweeted this afternoon that because of an "unexpected adverse financing situation" it would suspend its operations in the US. CNBC reported that it had laid off most of its staff.
The company says it is going to try to make a comeback and continues operations overseas. "I can clarify this temporarily affects US operations only," Mirza Cifric, the CEO of Veritas, said in an email. He said customers outside the US would continue to be served.
How does time dilation affect aging during high-speed space travel?
Your space questions, answered.
Advertisement